Comparing IVD Registration in Hong Kong and Indonesia

As the Asia-Pacific in vitro diagnostics (IVD) market continues to expand, manufacturers are increasingly looking at both Hong Kong and Indonesia as strategic entry points. While both jurisdictions regulate IVD products to ensure safety and performance, their regulatory systems differ significantly in structure, market approach, documentation requirements, and local representation obligations.

ElendiLabs has partnered with Product Registration Indonesia to support manufacturers navigating these regulatory pathways across Asia.

This article provides a comparison of IVD registration in Hong Kong and Indonesia, with a stronger focus on the Hong Kong framework. Detailed Indonesia-specific registration procedures can be found at Product Registration Indonesia – IVD Registration Indonesia.

---

Overview of IVD Regulation in Hong Kong

In Hong Kong, medical devices and IVDs are regulated under the Medical Device Administrative Control System (MDACS), managed by the Medical Device Division (MDD) of the Department of Health. Unlike many jurisdictions, MDACS is currently an administrative system rather than a statutory mandatory licensing regime for most products. However, listing under MDACS is strongly encouraged and increasingly expected by hospitals, healthcare providers, and procurement organizations.

Hong Kong’s regulatory framework aligns closely with international standards and adopts a risk-based classification approach similar to the Global Harmonization Task Force (GHTF) and IMDRF principles.

IVD Classification in Hong Kong

IVD devices in Hong Kong are classified into four risk classes:

• Class A – Low individual and public health risk
• Class B – Moderate individual risk / low public risk
• Class C – High individual risk / moderate public risk
• Class D – High individual and public health risk

Higher-risk devices require more comprehensive technical documentation, conformity assessment evidence, and post-market obligations.

Examples include:

Classification	Example
Class A	General laboratory reagents
Class B	Clinical chemistry assays
Class C	Blood glucose monitoring systems
Class D	HIV and hepatitis screening assays

---

Key Advantages of Hong Kong for IVD Manufacturers

1. Internationally Aligned Regulatory System

Hong Kong’s MDACS is designed around internationally recognized standards, making it attractive for overseas manufacturers already holding approvals from jurisdictions such as:

• European Union (CE marking)
• United States FDA
• Health Canada
• Australia TGA
• Japan PMDA

This alignment can simplify dossier preparation because many technical documents prepared for other major markets can also support Hong Kong submissions.

---

2. Efficient Market Access Strategy

Hong Kong is frequently used as:

• A regional commercial hub
• A gateway to Greater China and Asia-Pacific markets
• A reference market for distributors and hospitals

Although the Hong Kong population is smaller than Indonesia’s, the territory has a highly sophisticated healthcare system with strong adoption of advanced diagnostic technologies.

---

3. Local Responsible Person (LRP) Requirement

Foreign manufacturers without a local office must appoint a Local Responsible Person (LRP) in Hong Kong. The LRP acts as the official liaison with the Medical Device Division and is responsible for:

• Submission management
• Complaint handling
• Adverse event reporting
• Post-market surveillance
• Recall coordination

The choice of LRP is strategically important because the LRP becomes the regulatory representative for the listed product.

---

4. Technical Documentation Requirements

Hong Kong generally requires a Summary Technical Documentation (STED)-style dossier that may include:

• Device description
• Intended use
• Risk analysis
• Essential Principles checklist
• Labeling and IFU
• Clinical or performance evaluation
• Quality management system evidence
• Manufacturing information

For IVDs, performance evaluation data is particularly important, especially for higher-risk assays.

Manufacturers with ISO 13485 certification and existing approvals from recognized reference markets often experience a smoother review process.

---

5. Growing Importance of MDACS Listing

Although MDACS remains administrative in nature, listing is increasingly expected by:

• Public hospitals
• Private healthcare groups
• Laboratory procurement teams
• Distribution partners

Many institutional buyers now prefer or require MDACS-listed products before procurement consideration.

---

Overview of IVD Registration in Indonesia

Indonesia regulates IVDs through the Ministry of Health (MoH). All IVD devices must obtain a registration number and product license before they can be imported and commercially distributed in the country.

Indonesia follows a risk-based classification system aligned with ASEAN Medical Device Directive (AMDD) principles and GHTF guidance.

Key Features of the Indonesian IVD System

Mandatory Local License Holder

Foreign manufacturers cannot directly hold the registration. A licensed Indonesian distributor or local representative must hold the product license on behalf of the manufacturer.

Reference Country Approval Requirement

Indonesia generally requires prior approval from recognized reference markets before submission.

Risk-Based Timelines

Typical review timelines include:

IVD Class	Typical Timeline
Class A	~30 working days
Class B	~60 working days
Class C	~60 working days
Class D	~90 working days

Special Testing Requirements

Certain high-risk IVDs, such as HIV diagnostic kits, may require local testing through Indonesian reference laboratories.

For detailed Indonesian IVD registration procedures, documentation requirements, and local representation strategies, refer to:

Product Registration Indonesia – IVD Registration Indonesia

---

Hong Kong vs Indonesia: Key Differences

Area	Hong Kong	Indonesia
Regulatory Authority	Medical Device Division (MDD)	Ministry of Health (MoH)
Regulatory System	MDACS administrative system	Mandatory product licensing
IVD Classification	Class A–D	Class A–D
Local Representative Required	Yes (LRP)	Yes (local license holder/distributor)
Reference Country Approval	Helpful but not always mandatory	Typically required
Market Characteristics	Advanced healthcare hub	Large emerging market
Local Testing	Generally limited	Required for some high-risk IVDs
Language Requirements	English and Chinese labeling	Bahasa Indonesia labeling
License Validity	Listing-based system	Typically up to 5 years

---

Strategic Considerations for Manufacturers

Manufacturers expanding into Asia often approach Hong Kong and Indonesia differently:

Hong Kong as a Strategic Reference Market

Hong Kong is commonly prioritized for:

• Brand credibility
• Regional visibility
• Advanced healthcare adoption
• Access to sophisticated laboratories and hospitals

The internationally aligned system also makes Hong Kong attractive for innovative diagnostics and molecular testing platforms.

---

Indonesia for Commercial Scale

Indonesia offers:

• A very large population
• Expanding healthcare infrastructure
• Growing diagnostics demand
• Strong long-term commercial potential

However, manufacturers must carefully manage:

• Local distributor relationships
• License ownership strategy
• Bahasa Indonesia requirements
• Importation and post-market obligations

---

How ElendiLabs and Product Registration Indonesia Support Manufacturers

ElendiLabs provides regulatory support for medical devices and IVDs across Hong Kong and Asia-Pacific markets, including:

• Hong Kong MDACS submissions
• Technical dossier preparation
• Regulatory strategy
• Local Responsible Person support
• IVD classification assistance

For Indonesia-specific registration execution and local regulatory support, manufacturers can work with:

Product Registration Indonesia

Their local expertise can assist with:

• Indonesian MoH submissions
• Local license holder arrangements
• Importation coordination
• Bahasa Indonesia compliance
• Distributor and regulatory management

---

Conclusion

Hong Kong and Indonesia represent two very different but complementary opportunities for IVD manufacturers entering Asia.

Hong Kong offers an internationally aligned, efficient, and strategically valuable regulatory environment that supports market credibility and regional expansion. Indonesia, meanwhile, provides access to one of Southeast Asia’s largest healthcare markets through a more formalized licensing structure requiring local representation and compliance management.

By combining Hong Kong regulatory expertise from ElendiLabs with local Indonesian regulatory execution through Product Registration Indonesia, manufacturers can build a stronger and more efficient market entry strategy across the region.